Pashtoon M. Kasi, MD, MBBS, MS, discusses how genetic testing is underutilized in colorectal cancer, despite its ability to guide treatment dosing and adjustment based on the mutations or variations within a patient.
Pashtoon M. Kasi, MD, MBBS, MS, assistant professor of oncology and senior associate consultant in the Division of Hematology/Oncology at Mayo Clinic, discusses how genetic testing is underutilized in colorectal cancer (CRC), despite its ability to guide treatment dosing and adjustment based on the mutations or variations within a patient.
In CRC, specific genes are known to metabolize 5-fluorouracil, capecitabine, or irinotecan. Historical analyses have also shown that patients do much worse in regard to toxicities when given chemotherapy if they harbor a gene abberration, but Kasi says the frequency in which this aberration appears is underestimated.
Retrospective Data Demonstrates Efficacy of Regorafenib in mCRC
April 16th 2024During a Case-Based Roundtable® event, Madappa Kundranda, MD, PhD, discussed recent retrospective studies that compared outcomes between the available treatment options in patients with relapsed/refractory advanced colorectal cancer in the first article of a 2-part series.
Read More
Acalabrutinib/Obinutuzumab Shows Improved PFS in Treatment-Naive CLL
April 10th 2024In an interview with Targeted Oncology, Jeff Sharman, MD, discussed the results of the ELEVATE-TN trial of acalabrutinib with or without obinutuzumab at 74.5 months of follow-up among patients with chronic lymphocytic leukemia.
Read More